Pfizer Quality Improvement Request for Proposals: Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality Improvement
Supports Kazakhstan-based quality improvement projects to integrate molecular diagnostics and oncology data for enhanced precision cancer care in lung, breast, and prostate cancers.
Funder: Pfizer Inc.
Due Dates: June 2, 2026 (Submission deadline, full application)
Funding Amounts: Up to 5,000,000–10,000,000 KZT per project; project duration 1–2 years; 28% max overhead
Summary: Supports Kazakhstan-based quality improvement projects that integrate molecular diagnostics with oncology care data to enhance precision cancer treatment and planning.
Key Information: Only organizations (not individuals) in Kazakhstan are eligible; clinical research is not supported—focus is on data/process quality.
Description
This grant program, offered by Pfizer Inc., is designed to fund quality improvement (QI) initiatives in Kazakhstan that advance the integration, standardization, and quality of oncology data—especially molecular diagnostic information—within national or regional cancer care pathways. The focus is on adult advanced lung, breast, and prostate cancers, aiming to link actionable biomarker data with treatment processes and outcomes. Projects should address gaps in data quality, interoperability, and governance, supporting evidence-informed care delivery and national cancer control priorities. The program encourages multidisciplinary, data-driven approaches that improve data capture, standard operating procedures, and system interoperability to enable continuous improvement in cancer care.
